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Abstract
Background: Beta-blocker drugs are commonly used in family practice and studies showed that they were the
most popularly prescribed medications among all antihypertensive agents. This study aimed to identify the factors
associated with medication switching from a beta-blocker to another antihypertensive drug among Chinese
patients.
Methods: We used a validated database which consisted of the demographic and clinical information of all
Chinese patients prescribed a beta-blocker from any public, family practice clinics between 01 Jan 2004 to 30 June
2007 in one large Territory of Hong Kong. The proportion of patients switched from beta-blockers to another
antihypertensive agent 180 days within their first prescription was studied, and the factors associated with
medication switching were evaluated by using multivariate regression analyses.
Results: From 19,177 eligible subjects with a mean age of 59.1 years, 763 (4.0%) were switched from their beta-
blockers within 180 days of commencing therapy. A binary logistic regression model used medication switching as
the outcome variable and controlled for age, gender, socioeconomic status, clinic setting (general out-patient
clinics, family medicine specialist clinic or staff clinics), district of residence, visit type (new vs. follow-up
attendance), the number of concomitant co-morbidities, and the calendar year of prescription. It was found that
older patients (age 50-59 years: adjusted odds ratio [AOR] 1.38, 95% C.I. 1.12-1.70; p = 0.002; age 60-69 years: AOR
1.63 95% C.I. 1.30-2.04, p < 0.001; age ≥ 70 years: AOR 1.82, 95% C.I. 1.46-2.26, p < 0.001; referent age < 50 years)
and new visitors (AOR 0.57, 95% C.I. 0.48-0.68, p < 0.001) were more likely to have their medication switched.
Conclusions: Closer monitoring of the medication taking behavior among the older patients and the new clinic
visitors prescribed a beta-blocker is warranted. Future studies should evaluate the reasons of drug switching.
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Background
Hypertension is a global health problem and represents
one of the most important, modifiable risk factors for
renal and cardiovascular diseases [1] It affects more
than 30% of the general US population [2], and esti-
mates of the cost of the disorder are around $66.4 bil-
lion worldwide in 2007 [3]. Its prevalence is high over
the globe, including Asia Pacific countries [4]. Despite
the effectiveness of antihypertensive pharmacotherapy to
mitigate its complications [5,6], the control of hyperten-
sion remained suboptimal [7]. In family practice, its
total yearly costs were approximately £76.5 million, of
which £26.9 million was attributed to patients who dis-
continue or switch their pharmacotherapy [8].
Beta-blockers are commonly used in family practice to
manage a wide variety of chronic diseases, including
hypertension. Together with calcium channel blockers,
beta-blockers are one of the most commonly prescribed
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any medium, provided the original work is properly cited.antihypertensive agents in primary care settings [9]. The
clinical guidelines used in the clinics of the public sector
in Hong Kong were mainly from the 7
th Joint National
Committee Seventh Report. Therefore, the major antihy-
pertensive drug classes were regarded as equally accep-
table as first-line prescriptions for management of
arterial hypertension since 2003 [10]. In our recent stu-
dies on switching of antihypertensive drug therapies in
Hong Kong, we found that among more than 93,000
subjects with hypertension, 5.7% switched their medica-
tions to another antihypertensive drug class within 180
days of their prescriptions [11]. Subjects at higher risks
of medication switching were evaluated, and the risk
factors included young age, female gender, attendance in
family medicine clinics, new visitors and those pre-
scribed thiazide diuretics as well [11]. However when we
conducted stratified analysis of each antihypertensive
drug class in the same group of patients, the associated
factors of medication switching were different which sig-
nified a drug-class specific heterogeneity [12,13]. Beta-
blocker is a distinct group of antihypertensive agent
which has different efficacy depending on demographic
groups and other comorbid conditions [14].
Previous studies among Caucasian populations have
identified the risk factors associated with antihyperten-
sive drug switching [15-19]. Nevertheless, ethnicity
might be a factor which limits the generalizability of
these findings, since patients in the Asia Pacific region
might have a different profile of medication switching
due to different pharmacological actions of beta-block-
ers [20,21]. In particular, studies on patients of Chinese
ethnicity are particularly scarce despite the fact that
they constitute one-fifth of the world’s population. Chi-
nese patients were shown to be more sensitive to beta-
blockade effect when compared to white patients [22].
The primary objective of this study is to identify the
independent factors associated with switching of beta-
blockers in family practice. We tested the association
between age, gender, socioeconomic status, service set-
ting (general out-patient clinic [GOPC] or family medi-
cine specialist clinic [FMSC] or staff clinic), district of
residence, visit type (initial or follow-up visits) and the
number of co-morbidities, which were also the variables
tested in our previous studies [11-13].
Methods
Data Source
A detailed methodology has been presented elsewhere
[9,11,23]. The Clinical Data Analysis and Reporting Sys-
tem (CDARS) of the Hospital Authority (HA) of Hong
Kong consists of 7 million patient records, 1 million
annual admissions and 13 million ambulatory visits, with
research as one of its objectives [24]. The computerized
system consists of patients’ demographic and clinical
information, medical diagnoses in the forms of Interna-
tional Classification of Primary Care version 2 (ICPC-2)
codes, types of clinical services (location) and details on
medication prescriptions. This database has previously
been investigated and the demographic (100%) and pre-
scription details were 99.98%) complete [9].
When patients visit public primary care clinics in
Hong Kong, they register with their identity documents.
Socio-demographic information is recorded by the
reception staff, and entered into the computer system as
are drug prescription (with paper script back-up during
computer down-times) for both public and private sys-
tems.. All drug items were checked by two qualified dis-
pensers or pharmacists. Records are unified so that they
a r ea v a i l a b l ea ta n yp r i m a r yc a r ec l i n i c sw h e r et h e
patient presents. Clinical guidelines assist physicians to
enter the clinical diagnoses for each consultation using
ICPC-2 codes.
This study retrieved patient information from the New
Territory East cluster (NTE) of Hong Kong, which offers
primary healthcare services to approximately 1.3 million
residents, or 17.2% of the Hong Kong population [25].
The territory is further divided into three geographical
regions, namely Shatin (urbanized), Taipo and North
districts (rural). The median monthly household
incomes of residents in these three regions in 2006 were
US$2,510, US$2,338 and US$2,078, respectively, which
were comparable to the Hong Kong-wide figure of US
$2,240 [25]. The median ages in these three regions
were similar (38-39 years: median age of 39 years for
Hong Kong). We obtained ethical approval from the
Survey and Behavioural Research Ethics Committee of
the Chinese University of Hong Kong. All patients were
anonymized and their identities were replaced by unique
identifiers, hence informed consent was not required.
Definition of the cohort
All adult patients aged ≥ 18 years who attended a pri-
mary care clinic in the NTE region during the study
period January, 2004 to June, 2007, for whom at least
one antihypertensive medication was prescribed, were
included in our analysis. Each patient was assigned the
number of co-morbidities according to the number of
concomitant cardiovascular disorders other than ICPC-2
K86 [uncomplicated hypertension] (e.g., diabetes melli-
tus, cerebrovascular diseases, lipid disorders) and medi-
cal conditions which could potentially influence
prescription of a particular class of antihypertensive
drug (e.g., gout, asthma, ischemic heart diseases, benign
prostatic hypertrophy). Table 1 shows a complete list of
these medical conditions with their respective ICPC-2
codes.
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their prescription was computed. We defined drug
switching as “the absence of a refill prescription in all
subsequent clinic visits with issuance of another antihy-
pertensive drug of a different antihypertensive drug class
within the time frame of 180 days since the first pre-
scription date” [11]. A time frame of 180 days was used
instead of 90 days since the durations of antihyperten-
sive prescriptions were variable, ranging from 14 to 168
days (median 56 days).
Covariates and statistical analysis
We used the same variables in a previous study [11] to
test for associations with the primary outcome, namely
medication switching 180 days within their prescrip-
tions. The covariates included age, gender, socioeco-
nomic status in terms of fee-payers vs. fee-waivers,
service type, district of residence, visit type, the number
of comorbidities and the calendar years of prescriptions.
Fee waivers are mainly subjects receiving social security
allowances from the government. To apply for fee waiv-
ing, applicants will receive a comprehensive assessment
by a professional in the social welfare sector in order to
certify their inability to pay for clinical consultation fees.
Each consultation charges US$5.77, including investiga-
tion and medication fees. We defined new visitors as
patients who have never been prescribed any antihyper-
tensive medications in any clinics under HA. One
unconditional, binary logistic regression analysis was
conducted of all eligible patients, and all the predictor
variables were entered into the regression models. The
Statistical Package for Social Sciences version 15.0 (SPSS
Incorporation, Chicago Illinois) was used for all data
analysis. All p values ≤ 0.05 were regarded as statistically
significant.
Results
A total of 19,177 eligible patients were included in the
present study. 41.5% were aged ≥ 60 years, and the
majority were female (62.8%) (Table 2). Most were fee-
payers (73.5%), attended GOPCs for the consultations
(90.2%), lived in more urbanized regions (Shatin and
Taipo: 70.8%), and were first-ever visitors (61.6%).
Among them, 83.2% had no co-morbidities, and most
prescriptions were issued in the calendar years 2004
(51.2%) and 2005 (22.7%).
Table 3 shows the characteristics of patients who
switched compared with those who continued their
beta-blocker prescriptions. A total of 4.0% switched
their medication within 180 days. When compared with
drug continuers, those who switched their prescriptions
were older, more were female (64.0% vs. 62.8%), fee
payers (73.9% vs. 73.4%), and visitors of GOPCs (91.9%
v s .9 0 . 1 % )( a l lp<0 . 0 0 1 ) .I na d d i t i o n ,m o r ep a t i e n t s
who switched lived in more rural districts (the North
region; 24.4% vs. 22.0%), were new visitors (74.7% vs.
61.1%) and had more co-morbidities (17.3% vs. 16.7%)
(all p < 0.001).
From a binary logistic regression model, patients who
were older (≥ 50 years; adjusted odds ratio [AOR] ran-
ged from 1.38 to 1.82) and new clinic visitors (AOR for
follow-up visitors = 0.57, 95% C.I. 0.48 to 0.68, p <
0.001) were significantly more likely to have their medi-
cation switched (Table 4). There were no statistically
significant associations detected between other covari-
ates with the outcome variable. When we used 240 days
and 360 days as the yardsticks of medication switching
and re-conducted the regression analyses, similar signifi-
cant associations were detected for age and visit type.
There existed no multi-coline a r i t yf o rt h er e g r e s s i o n
models, suggesting their statistical robustness.
Discussion
From this retrospective cohort consisting of 19,177
Chinese patients, we reported that older age and first
clinic visits were significant predictors of medication
switching. The other factors previously shown to be
associated with antihypertensive drug switching [11],
including gender, service type, district of residence, visit
type and co-morbidities, were no longer statistical signif-
icant. Thus far there were no studies of this scale which
Table 1 Comorbidities according to the respective
International Classification of Primary Care (ICPC) Codes
ICPC codes Disease entity
T90 Diabetes Mellitus
T901 Impaired glucose tolerance
T92 Gout
T93 Lipid disorders
K90 Stroke/cerebrovascular accident
K91 Cerebrovascular disease
K74 Ischemic Heart Disease with angina
K76 Ischemic Heart Disease without angina
K75 Acute Myocardial Infarction
K77 Heart Failure
K84 Heart Disease, other
K99 Cardiovascular disease, other
R79 Chronic Bronchitis
R95 Chronic Obstructive Pulmonary Disease
R96 Asthma
U14 Kidney symptoms/complaints
U88 Glomerulonephritis/nephrosis
Y85 Benign Prostatic Hypertrophy
U78 Benign Neoplasm Urinary Tract
Y79 Benign/unspecified neoplasm, male genital
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beta-blocker to another antihypertensive prescription.
The mechanism where beta-blockers lower blood pres-
sure could be multifactorial [26]. Some suggested
mechanisms included diminution of sympathetic outflow
mediated by the effect of the central nervous system, and
reduced cardiac output accompanied by increased periph-
eral resistance [27]. Among the elderly, hypertension is
characterized by compromised cardiac output and esca-
lated peripheral vascular resistance [28,29]. Beta-blockers
used in the long term may lead to homeostatic adjust-
ments that can improve cardiac output but will then be
depressed when compared with the original state.
Furthermore, there has been evidence that lipophilic
beta-blockers can easily cross the blood-brain barrier,
Table 2 Patient characteristics (N = 19,177)
No. %
Age (years)
< 50 5,327 27.8
50-59 5,885 30.7
60-69 3,863 20.1
≥ 70 4,102 21.4
Gender
Male 7,133 37.2
Female 12,044 62.8
Payment status
Fee waivers 5,088 26.5
Fee payers 14,089 73.5
Service type
GOPC 17,294 90.2
FMSC 1,704 8.9
Staff clinic 179 0.9
District of residence
Shatin 8,905 46.4
Taipo 4,684 24.4
North 4,246 22.1
Others 1,342 7.0
Visit type
New 11,817 61.6
Old 7,360 38.4
Comorbidities
0 15,952 83.2
1 2,774 14.5
2 432 2.3
> 3 19 0.1
Calendar years of prescription
2004 9,826 51.2
2005 4,360 22.7
2006 3,402 17.7
2007 1,589 8.3
GOPC: General Out-patient Clinic; FMSC: Family Medicine Specialist Clinic; CCB:
Calcium Channel Blockers; All the percentages are across columns
Table 3 Characteristics of beta-blockers switchers and
non-switchers (N = 19,177)
Switchers
(n = 763)
non-switchers
(n = 18,414)
p
No. % No. %
Age (years)
< 50 158 20.7 5,169 28.1 < 0.001
50-59 229 30.0 5,656 30.7
60-69 171 22.4 3,692 20.0
≥ 70 205 26.9 3,897 21.2
Gender
Male 275 36.0 6,858 37.2 < 0.001
Female 488 64.0 11,556 62.8
Payment status
Fee waivers 199 26.1 4,889 26.6 < 0.001
Fee payers 564 73.9 13,525 73.4
Service type
GOPC 701 91.9 16,593 90.1 < 0.001
FMSC 59 7.7 1,645 8.9
Staff clinic 3 0.4 176 1.0
District of residence
Shatin 357 46.8 8,548 46.4 < 0.001
Taipo 177 23.2 4,507 24.5
North 186 24.4 4,060 22.0
Others 43 5.6 1,299 7.1
Visit type
New 570 74.7 11,247 61.1 < 0.001
Old 193 25.3 7,167 38.9
Comorbidities
0 630 82.6 15,322 83.2 < 0.001
1 114 14.9 2,660 14.4
≥ 2 19 2.5 432 2.3
Calendar years of prescription
2004 279 36.6 9,547 51.8 < 0.001
2005 227 29.8 4,133 22.4
2006 189 24.8 3,213 17.4
2007 68 8.9 1,521 8.3
GOPC: General Out-patient Clinic; FMSC: Family Medicine Specialist Clinic. All
the percentages were across columns.
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function in older subjects [30]. In addition, beta-blockers
have strong potentials to induce conduction abnormal-
ities, undesirable bradycardia, and development of heart
failure especially among elderly with left ventricular dys-
function [30-32].
Evidence points towards the relative ineffectiveness of
beta-blockers as a treatment regimen for hypertension
among the elderly populations. For instance, one meta-
analysis including more than 16,000 elderly subjects 60
years or older reported that beta-blockers were incap-
able to prevent coronary heart diseases, fatal or non-
fatal myocardial infarctions [33]. Also, when compared
with other antihypertensive therapies, beta-blockers
were the least effective in reducing left ventricular mass
in the elderly although the effects on blood pressure
lowering were similar across major antihypertensive
drug classes [34-36]. Therefore with an exception of the
Joint National Committee 7
th report, beta-blocker has
not been recommended as a first-line agent in the
elderly without any concomitant disorders like conges-
tive heart failure or myocardial infarction [37].
Medication switching is essentially a physician-
initiated action, but the patient could have influence.
The physician might perceive the initial beta-blocker
regimen is better replaced by a more efficacious antihy-
pertensive medication to control blood pressure or
other cardiovascular risk factors. For instance, elderly
patients are more likely to suffer from poorly controlled
diabetes and impaired glucose tolerance, and switching
of beta-blockers to another agent is warranted. It can
also be patient-driven, like a complaint of intolerable
adverse events. Our findings that older subjects were
more likely to have their beta-blockers switched could
be explained by either or both of the above reasons.
That the new visitors were more likely to have their
medication switched is not surprising, as the follow-up
patients might already have refilled their medications for
at least once and should be arguably free of adverse
effects when compared with the new clinic attendees.
Our study included a large number of Chinese sub-
jects. The good dispensing practice in the primary care
out-patient clinics allowed an accurate analysis of pre-
scription patterns free of recall biases. However some
limitations should be mentioned. Firstly this study
included a Chinese population from only one geographi-
c a lr e g i o no u to fs e v e ni nH o n gK o n g ,a l t h o u g ht h e
demographic features of our samples are similar to all
residents in Hong Kong. In addition, we captured only
short-term switching profiles, and longer term prescrip-
tion changes could not be assessed. Furthermore,
the reasons of medication switching could not be evalu-
ated from retrospective database analyses, and there
remained some confounding factors like blood pressure
level, body mass index, lifestyle habits and attitudes
towards taking of chronic medications which could not
be controlled for.
Conclusions
The implication of this study is that more careful prac-
tice of prescribing beta-blockers is needed particularly
among the elderly and also the new visitors, who are
more likely to be drug-naive. Translated into clinical
practice, family physicians should attempt closer moni-
toring of the medication taking behavior of their
patients with these risk factors. In the broader context
of primary care, a multidisciplinary team of healthcare
Table 4 Factors associated with switching of beta-
blockers (N = 19,177, r
2 =0
No. % Adjusted odds ratios
(95% C.I.)
p
Age
< 50 158 3.0 1.00 (reference)
50-59 229 3.9 1.38 (1.12-1.70) 0.002
60-69 171 4.4 1.63 (1.30-2.04) < 0.001
≥ 70 205 5.0 1.82 (1.46-2.26) < 0.001
Gender
Female 275 2.3 1.00 (reference)
Male 488 6.8 0.89 (0.76-1.03) 0.125
Payment status
Fee waivers 199 3.9 1.00 (reference)
Fee payers 564 4.0 1.02 (0.87-1.21) 0.792
Service type
GOPC 701 4.1 1.00 (reference)
FMSC 59 3.5 0.97 (0.73-1.28) 0.817
Staff clinic 3 1.7 0.47 (0.15-1.48) 0.196
District of residence
Shatin 357 4.0 1.00 (reference)
Taipo 177 3.8 0.95 (0.79-1.15) 0.606
North 186 4.4 1.07 (0.88-1.29) 0.505
Others 43 3.2 0.82 (0.59-1.13) 0.223
Visit type
New 570 4.8 1.00 (reference)
Old 193 2.6 0.57 (0.48-0.68) < 0.001
Comorbidities
0 630 3.9 1.00 (reference)
1 114 4.1 1.17 (0.95-1.45) 0.150
≥ 2 19 4.2 1.23 (0.76-2.00) 0.396
GOPC: General Out-patient Clinic; FMSC: Family Medicine Specialist Clinic; CCB:
Calcium Channel Blockers; RAS: Drugs acting on the rennin-angiotensin
system. %: represents the percentages of patients with drugs discontinued.
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Page 5 of 7professionals should collaborate and strengthen medica-
tion management in the community. This could involve
community pharmacists who can give timely advice to
patients regarding medication counseling and support.
The future direction of research should be targeted
towards the reasons of medication switching, and to
what degree family physicians were influenced by evi-
dence-based guidelines regarding prescription of first-
line antihypertensive agents.
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